open access

Vol 74, No 4 (2023)
Original paper
Submitted: 2023-02-22
Accepted: 2023-06-04
Published online: 2023-07-27
Get Citation

A comparison of the 2 thermal ablation procedures for the management of benign thyroid nodules

Süleyman Sönmez1, Elif Önder2, Mehtap Navdar Başaran2, Hatice Çalışkan3, Yıldıray Topçu3, Sevcan Genç4, Hande Peynirci2
·
Pubmed: 37577995
·
Endokrynol Pol 2023;74(4):392-397.
Affiliations
  1. Department of Radiology, University of Health Sciences, Kanuni Sultan Süleyman Research and Training Hospital, Istanbul, Türkiye
  2. Department of Endocrinology and Metabolism, University of Health Sciences, Kanuni Sultan Süleyman Research and Training Hospital, Istanbul, Türkiye
  3. Department of Geriatric Medicine, University of Health Sciences, Kanuni Sultan Süleyman Research and Training Hospital, Istanbul, Türkiye
  4. Department of Internal Medicine, University of Health Sciences, Kanuni Sultan Süleyman Research and Training Hospital, Istanbul, Türkiye

open access

Vol 74, No 4 (2023)
Original Paper
Submitted: 2023-02-22
Accepted: 2023-06-04
Published online: 2023-07-27

Abstract

Introduction: In recent years, ultrasound (US)-guided thermal ablation techniques have come to the fore as minimally invasive alternatives to surgery. The purpose of this study was to assess the effectiveness and safety of radiofrequency ablation or microwave ablation procedures in patients with benign thyroid nodules.

Material and methods: This retrospective and single-centre study consisted of 55 patients and 62 benign thyroid nodules that were treated either with radiofrequency ablation (RFA) or microwave ablation (MWA) in our hospital between January 2020 and March 2022. All the patients were at high risk for surgery or with symptomatic TNs and who refused surgery. The TNs diagnosed as benign from the fine-needle aspiration biopsy were evaluated in terms of volume reduction, symptom, and cosmetic scores. In addition, these 2 treatment modalities were compared to each other.

Results: Out of 55 patients, 44 (80%) were female and were aged between 24 and 97 years with a median age of 50 years. RFA was applied to 54.5% (n = 30) of the participants, and MWA was applied to 46.5% (n = 25). The volume reduction rate (VRR) after RFA and MWA at the first month was 63.4 ± 14.2 and 65.7 ± 13, respectively. No significant difference was detected between the 2 groups in terms of VRR (p = 0.51). In addition, the mean symptom and cosmetic scores decreased significantly in both procedures, and there was a significant difference due to the symptom score change in the RFA group compared to the MWA group. Of all the patients, one patient experienced haematoma in the RFA, and one patient had transient voice change in the MWA group. No life-threatening complications were noted.

Conclusion: In the treatment of benign symptomatic thyroid nodules, both RFA and MWA are options worthy of consideration in terms of efficacy and safety.

Abstract

Introduction: In recent years, ultrasound (US)-guided thermal ablation techniques have come to the fore as minimally invasive alternatives to surgery. The purpose of this study was to assess the effectiveness and safety of radiofrequency ablation or microwave ablation procedures in patients with benign thyroid nodules.

Material and methods: This retrospective and single-centre study consisted of 55 patients and 62 benign thyroid nodules that were treated either with radiofrequency ablation (RFA) or microwave ablation (MWA) in our hospital between January 2020 and March 2022. All the patients were at high risk for surgery or with symptomatic TNs and who refused surgery. The TNs diagnosed as benign from the fine-needle aspiration biopsy were evaluated in terms of volume reduction, symptom, and cosmetic scores. In addition, these 2 treatment modalities were compared to each other.

Results: Out of 55 patients, 44 (80%) were female and were aged between 24 and 97 years with a median age of 50 years. RFA was applied to 54.5% (n = 30) of the participants, and MWA was applied to 46.5% (n = 25). The volume reduction rate (VRR) after RFA and MWA at the first month was 63.4 ± 14.2 and 65.7 ± 13, respectively. No significant difference was detected between the 2 groups in terms of VRR (p = 0.51). In addition, the mean symptom and cosmetic scores decreased significantly in both procedures, and there was a significant difference due to the symptom score change in the RFA group compared to the MWA group. Of all the patients, one patient experienced haematoma in the RFA, and one patient had transient voice change in the MWA group. No life-threatening complications were noted.

Conclusion: In the treatment of benign symptomatic thyroid nodules, both RFA and MWA are options worthy of consideration in terms of efficacy and safety.

Get Citation

Keywords

benign thyroid nodules; radiofrequency ablation; microwave ablation; volume reduction rate; symptom and cosmetic scores

About this article
Title

A comparison of the 2 thermal ablation procedures for the management of benign thyroid nodules

Journal

Endokrynologia Polska

Issue

Vol 74, No 4 (2023)

Article type

Original paper

Pages

392-397

Published online

2023-07-27

Page views

980

Article views/downloads

341

DOI

10.5603/EP.a2023.0051

Pubmed

37577995

Bibliographic record

Endokrynol Pol 2023;74(4):392-397.

Keywords

benign thyroid nodules
radiofrequency ablation
microwave ablation
volume reduction rate
symptom and cosmetic scores

Authors

Süleyman Sönmez
Elif Önder
Mehtap Navdar Başaran
Hatice Çalışkan
Yıldıray Topçu
Sevcan Genç
Hande Peynirci

References (21)
  1. Morris LGT, Sikora AG, Tosteson TD, et al. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid. 2013; 23(7): 885–891.
  2. Hegedüs L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003; 24(1): 102–132.
  3. Welker MJo, Orlov D. Thyroid nodules. Am Fam Physician. 2003; 67(3): 559–566.
  4. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26(1): 1–133.
  5. Garberoglio R, Aliberti C, Appetecchia M, et al. Radiofrequency ablation for thyroid nodules: which indications? The first Italian opinion statement. J Ultrasound. 2015; 18(4): 423–430.
  6. Gharib H, Papini E, Garber JR, et al. AACE/ACE/AME Task Force on Thyroid Nodules. American Association Of Clinical Endocrinologists, American College Of Endocrinology, And Associazione Medici Endocrinologi Medical Guidelines For Clinical Practice For The Diagnosis And Management Of Thyroid Nodules — 2016 Update. Endocr Pract. 2016; 22(5): 622–639.
  7. Papini E, Monpeyssen H, Frasoldati A, et al. 2020 European Thyroid Association Clinical Practice Guideline for the Use of Image-Guided Ablation in Benign Thyroid Nodules. Eur Thyroid J. 2020; 9(4): 172–185.
  8. Shin JH, Baek JH, Chung J, et al. Korean Society of Thyroid Radiology (KSThR) and Korean Society of Radiology. Ultrasonography Diagnosis and Imaging-Based Management of Thyroid Nodules: Revised Korean Society of Thyroid Radiology Consensus Statement and Recommendations. Korean J Radiol. 2016; 17(3): 370–395.
  9. Na DG, Lee JH, Jung SoL, et al. Korean Society of Thyroid Radiology (KSThR), Korean Society of Radiology. Radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: consensus statement and recommendations. Korean J Radiol. 2012; 13(2): 117–125.
  10. Gharib H, Hegedüs L, Pacella CM, et al. Clinical review: Nonsurgical, image-guided, minimally invasive therapy for thyroid nodules. J Clin Endocrinol Metab. 2013; 98(10): 3949–3957.
  11. Papini E, Pacella CM, Hegedus L. Diagnosis of endocrine disease: thyroid ultrasound (US) and US-assisted procedures: from the shadows into an array of applications. Eur J Endocrinol. 2014; 170(4): R133–R146.
  12. Bisceglia A, Rossetto R, Garberoglio S, et al. Predictor Analysis in Radiofrequency Ablation of Benign Thyroid Nodules: A Single Center Experience. Front Endocrinol (Lausanne). 2021; 12: 638880.
  13. Wu W, Gong X, Zhou Qi, et al. US-guided percutaneous microwave ablation for the treatment of benign thyroid nodules. Endocr J. 2017; 64(11): 1079–1085.
  14. Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. Radiographics. 2005; 25 Suppl 1: S69–S83.
  15. Zhi X, Zhao N, Liu Y, et al. Microwave ablation compared to thyroidectomy to treat benign thyroid nodules. Int J Hyperthermia. 2018; 34(5): 644–652.
  16. Luo F, Huang L, Gong X, et al. Microwave ablation of benign thyroid nodules: 3-year follow-up outcomes. Head Neck. 2021; 43(11): 3437–3447.
  17. Yue WW, Wang SR, Lu F, et al. Radiofrequency ablation vs. microwave ablation for patients with benign thyroid nodules: a propensity score matching study. Endocrine. 2017; 55(2): 485–495.
  18. Javadov M, Karatay E, Ugurlu MU. Clinical and functional results of radiofrequency ablation and microwave ablation in patients with benign thyroid nodules. Saudi Med J. 2021; 42(8): 838–846.
  19. Cheng Z, Che Y, Yu S, et al. US-Guided Percutaneous Radiofrequency versus Microwave Ablation for Benign Thyroid Nodules: A Prospective Multicenter Study. Sci Rep. 2017; 7(1): 9554.
  20. Hussain I, Zulfiqar F, Li X, et al. Safety and Efficacy of Radiofrequency Ablation of Thyroid Nodules-Expanding Treatment Options in the United States. J Endocr Soc. 2021; 5(8): bvab110.
  21. Nguyen VB, Nguyen TX, Nguyen VV, et al. Efficacy and Safety of Single-Session Radiofrequency Ablation in Treating Benign Thyroid Nodules: A Short-Term Prospective Cohort Study. Int J Endocrinol. 2021; 2021: 7556393.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl